Results 231 to 240 of about 12,044 (250)
Some of the next articles are maybe not open access.
Penicillamine-Induced Ocular Myasthenia Gravis
American Journal of Ophthalmology, 1985Two patients with rheumatoid arthritis (two women, 58 and 62 years old) developed reversible penicillamine-induced ocular myasthenia gravis. Both had the HLA-DR1 antigen, unlike most patients with idiopathic myasthenia gravis who show HLA-DR3, suggesting that penicillamine-induced myasthenia gravis and its idiopathic counterpart occur in patients with ...
M, O'Keefe +3 more
openaire +2 more sources
Update on Ocular Myasthenia Gravis
Neurologic Clinics, 2017Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis in which autoantibodies directed against acetylcholine receptors block or destroy these receptors at the postsynaptic neuromuscular junction. The hallmark of OMG is a history of painless weakness or fatigability of the extraocular muscles and ptosis with normal pupillary function ...
Stacy V, Smith, Andrew G, Lee
openaire +2 more sources
Klinische Monatsblatter fur Augenheilkunde, 1985
Ocular myasthenia is a special form of general myasthenia gravis characterized by unilateral or bilateral ptosis and eye muscle pareses of distinct variability, depending on the time of day and the state of fatigue of the patient. Most important for diagnosis is the Tensilon test, which can, however, produce negative results.
openaire +1 more source
Ocular myasthenia is a special form of general myasthenia gravis characterized by unilateral or bilateral ptosis and eye muscle pareses of distinct variability, depending on the time of day and the state of fatigue of the patient. Most important for diagnosis is the Tensilon test, which can, however, produce negative results.
openaire +1 more source
Archives of Neurology, 1997
In their discussion of the results of a retrospective chart review of 32 patients with ocular myasthenia gravis treated with prednisone for variable periods, Kupersmith and colleagues 1 neglected to mention the only controlled clinical trial of anything in myasthenia—namely, of corticotropin.
openaire +1 more source
In their discussion of the results of a retrospective chart review of 32 patients with ocular myasthenia gravis treated with prednisone for variable periods, Kupersmith and colleagues 1 neglected to mention the only controlled clinical trial of anything in myasthenia—namely, of corticotropin.
openaire +1 more source
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2013
Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to provide a pragmatic approach to the pathogenesis, clinical features, diagnostics and therapeutic strategies in the clinical routine.
S, Pitz, B, Jordan, S, Zierz
openaire +1 more source
Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to provide a pragmatic approach to the pathogenesis, clinical features, diagnostics and therapeutic strategies in the clinical routine.
S, Pitz, B, Jordan, S, Zierz
openaire +1 more source
Oftalmologia (Bucharest, Romania : 1990), 2012
The authors present a case of ocular myastenia, suspected by an ophthalmologist and confirmed as diagnosis by a neurologist. There are discussion regarding the latest possibilities of treatment.
Andreea-Madalina, Stefanescu +3 more
openaire +1 more source
The authors present a case of ocular myastenia, suspected by an ophthalmologist and confirmed as diagnosis by a neurologist. There are discussion regarding the latest possibilities of treatment.
Andreea-Madalina, Stefanescu +3 more
openaire +1 more source
Journal of the National Medical Association, 1994
Ocular dysfunction accounts for nearly 70% of the initial manifestations of myasthenia gravis. Since the prevalence rate of myasthenia gravis is two to 10 cases per 100,000 population, it is important for clinicians to be cognizant of this disorder and its varied ocular presentations.
G A, March, L N, Johnson
openaire +1 more source
Ocular dysfunction accounts for nearly 70% of the initial manifestations of myasthenia gravis. Since the prevalence rate of myasthenia gravis is two to 10 cases per 100,000 population, it is important for clinicians to be cognizant of this disorder and its varied ocular presentations.
G A, March, L N, Johnson
openaire +1 more source